September 11, 2019
House Speaker Nancy Pelosi (D-Calif.) as early as this week could release a bill to tackle rising prescription drug costs—and a summary of the bill obtained by media outlets suggests Pelosi is considering allowing HHS to negotiate drug prices for certain treatments and establishing a drug price ceiling based on the prices paid for the drugs in other countries.
As the debate around health care prices continues, some providers are turning to Groupon to get new patients in the door with deals on health care services—a trend that has persisted despite the industry's efforts to move away from volume-driven care.
September 9, 2019
Major insurers are eyeing and developing new strategies to help employers cover the cost of gene therapies priced at millions of dollars per treatment.
September 6, 2019
Sean Blake died of a drug-related overdose in August 2017, after nearly a decade cycling in and out of substance use disorder (SUD) treatment programs that cost his family $110,000—a story that highlights the flaws in the U.S. SUD treatment system.
September 5, 2019
Medicare Part D in 2016 unnecessarily spent an estimated $161 million on drugs that already were covered under Medicare Part A, according to an HHS Office of Inspector General report released last week.
A California law touted as a national model for addressing so-called "surprise" medical bills has led to fewer surprise bills for patients and lower payment rates for in-network and out-of-network physicians—but it might be driving physician group consolidation, according to recent research.
September 4, 2019
CMS on Thursday rejected Idaho's request to expand the state's Medicaid program, but allow individuals who are eligible for the expanded program to remain enrolled in Affordable Care Act exchange plans.
September 3, 2019
Rising prices for multiple sclerosis drugs drove a more than sevenfold increase in out-of-pocket costs for Medicare Part D beneficiaries over a decade, according to a study published last week in JAMA Neurology.
August 28, 2019
Dawn Patterson and two of her children have a rare bone disease, and the only treatment is a drug that was slated to cost $6 million a year—a high price tag that observers say is indicative of the pharmaceutical industry's growing interest in treatment for rare diseases.
August 27, 2019
A district court judge on Monday ruled that Johnson & Johnson contributed to Oklahoma's opioid crisis by downplaying the risks of its opioid drugs and ordered the company to pay the state $572 million.
Advisory Board. All rights reserved.